Bausch + Lomb (BLCO) President Luc Bonnefoy Sells $15K of Stock
Luc Bonnefoy, BLCO's President of Surgical, sold 1,008 shares on June 12.
Reviewed by automated data checks against the source filing. How we make and check alerts
Luc Bonnefoy, President, Surgical at Bausch + Lomb Corporation ($BLCO), sold 1,008 shares at an average price of $15.08, worth about $15,200.64, on June 12, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $BLCO is down 1.0% after 1 week, up 7.5% after 1 month and up 9.3% to date (from the $15.08 close on Jun 12, 2026).
BLCO
Bausch + Lomb Corporation
Key Points
- Luc Bonnefoy, President of Surgical at BLCO, sold 1,008 shares for about $15,200.64 on June 12, 2026.
- BLCO shares are trading around $15.00 with active institutional interest from Deutsche Bank and D. E. Shaw.
- Analysts from firms like Evercore and Citigroup have maintained their ratings with price targets ranging from $16 to $21.
Get $BLCO trade alerts by text
We text you when insiders, Congress or big funds trade $BLCO. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Bausch + Lomb Corporation alert may contain errors. Disclosures
Luc Bonnefoy, President of Surgical at BLCO, sold 1,008 shares of the company on June 12, 2026. The shares were sold at an average price of $15.08 each, totaling approximately $15,200.64. This transaction was not part of a pre-planned trading program.
Other Institutional Activity in BLCO
BLCO has seen varied activity from institutional investors. Deutsche Bank AG added 78,441 shares, bringing its total to 3,528,441 shares valued at about $56.1 million. D. E. Shaw & Co., Inc. significantly increased its position by 304,542 shares to a total of 3,151,167 shares worth approximately $50.1 million. Meanwhile, Silver Point Capital L.P. reduced its holdings by 320,000 shares, now holding 2,245,000 shares valued at $35.7 million.
Bausch + Lomb Corporation Stock Down 11.0%
BLCO shares are currently trading at approximately $15.00. The stock has been active with a 52-week range between $14.00 and $18.00. The company's market dynamics are closely watched, with a mix of buying and selling from both insiders and institutional investors.
Insider Buying and Selling at Bausch + Lomb Corporation
In addition to Luc Bonnefoy's sale, several insiders made notable transactions in late May. On May 26, Karen Ling, Russel Robertson, Steven Collis, John Paulson, and Thomas Ross Sr. each purchased 15,842 shares at an average price of $15.78.
Analysts Set New Price Targets
Analysts have maintained their positions on BLCO with various price targets. On April 30, 2026, Evercore ISI Group maintained a 'hold' rating with a $16 target. Citigroup and HC Wainwright & Co. have more optimistic views, maintaining 'buy' ratings with targets of $21 and $20, respectively, back in February.
Bottom Line
Luc Bonnefoy's recent sale is part of ongoing insider activity at BLCO, reflecting individual strategies rather than an overall trend. BLCO's stock remains under close watch by institutional investors and analysts, with varied opinions on its future performance. As always with 13F filings and insider transactions, these moves provide a snapshot of past actions, not necessarily current positions.
Related Filing Alerts
Source: Luc Bonnefoy's Form 4 filing on $BLCO (Jun 12, 2026). Find the original filing: BLCO Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts